- Synthesis of beta-adrenomimetic excitant type fodder additive, China, , ,
Cas no 90274-24-1 (rac Ractopamine Hydrochloride (Mixture of Diastereomers))
Rac Ractopamine Hydrochloride is a synthetic β-adrenergic agonist composed of a mixture of diastereomers, primarily used as a feed additive to promote lean muscle growth in livestock. Its hydrochloride form enhances stability and solubility, ensuring consistent bioavailability. The racemic mixture provides a balanced pharmacological profile, leveraging the synergistic effects of its stereoisomers. This compound is characterized by high selectivity for β1 and β2 adrenergic receptors, facilitating efficient protein synthesis and fat reduction in animals. Rigorous quality control ensures compliance with regulatory standards, making it a reliable choice for veterinary and agricultural applications. Its well-documented efficacy and safety profile support its use in optimized livestock production systems.
90274-24-1 structure
Product Name:rac Ractopamine Hydrochloride (Mixture of Diastereomers)
CAS No:90274-24-1
MF:C18H24ClNO3
MW:337.841064453125
MDL:MFCD07781271
CID:61392
PubChem ID:14010333
Update Time:2025-06-29
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Chemical and Physical Properties
Names and Identifiers
-
- 4-(1-Hydroxy-2-((4-(4-hydroxyphenyl)butan-2-yl)amino)ethyl)phenol hydrochloride
- 4-[3-[2-Hydroxy-2-(4-hydroxyphenyl)-ethyl]aminobutyl]phenol hydrochloride
- Benzenemethanol, 4-hydroxy-alpha-(((3-(4-hydroxyphenyl)-1-methylpropyl)amino)methyl)-, hydrochloride
- RACTOPAMINE HCL
- Ractopamine Hydrochloride
- 4-[3-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]butyl]phenol,hydrochloride
- rac Ractopamine Hydr
- rac Ractopamine Hydrochloride
- Ractopamine hydrochloride solution
- Benzenemethanol, 4-hydroxy-α-[[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]methyl]-, hydrochloride (9CI)
- EL 737
- LY 031537
- LY O31537
- Optaflexx
- Paylean
- Topmax 9
- Actogain
- LYO-31537
- UNII-309G9J93TP
- Pharmakon1600-01502332
- D05691
- NSC-759638
- Ractopamine hydrochloride [USAN]
- EC 415-170-5
- EL 737; LY 031537; LY O31537; Optaflexx; Paylean;Topmax 9
- AKOS015961286
- Ractopamine hydrochloride, United States Pharmacopeia (USP) Reference Standard
- NCGC00164602-01
- Engain 9
- DTXSID1046471
- El737
- DTXCID9026471
- Paylean 45
- RACTOPAMINE HYDROCHLORIDE [GREEN BOOK]
- RAC 45 CATTLE
- SW220070-1
- 1ST1307A
- SCHEMBL350754
- 90274-24-1
- Topmax
- AT25794
- (+/-)-ALL-RAC-P-HYDROXY-.ALPHA.-(((3-(P-HYDROXYPHENYL)-1-METHYLPROPYL)AMINO)METHYL)BENZYL ALCOHOL, HYDROCHLORIDE
- EL-737
- CHEMBL2105358
- (+-)-all-rac-p-Hydroxy-alpha-(((3-(p-hydroxyphenyl)-1-methylpropyl)amino)methyl)benzyl alcohol, hydrochloride
- RACTOPAMINE HYDROCHLORIDE [USP IMPURITY]
- Optaflexx 45
- Ractopamine hydrochloride, VETRANAL(TM), analytical standard
- NSC759638
- MFCD07781271
- 4-{3-[2-Hydroxy-2-(4-hydroxyphenyl)ethyl]aminobutylphenol hydrochloride
- (+/-)-all-rac-p-Hydroxy-alpha-(((3-(p-hydroxyphenyl)-1-methylpropyl)amino)methyl)benzyl alcohol, hydrochloride
- RACTOPAMINE HYDROCHLORIDE [USP-RS]
- Tox21_112224
- BENZENEMETHANOL, 4-HYDROXY-.ALPHA.-(((3-(4-HYDROXYPHENYL)-1-METHYLPROPYL)AMINO)METHYL)-, HYDROCHLORIDE
- LYO31537
- Optigrid 45
- CCG-213033
- Butopamine-d4Hydrochloride
- Paylean 9
- Actogain 45
- Q27255947
- AS-13956
- RACTOPAMINE HYDROCHLORIDE [MI]
- Ractopamine HCl - 95%
- Ractopamine (hydrochloride)
- 309G9J93TP
- BR164308
- DB-057193
- (+/-)-4-(2-((3-(4-Hydroxyphenyl)-1-methylpropyl)amino)-1-hydroxyethyl)phenol hydrochloride
- Engain 9 and Engain 45
- 4-[3-[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]butyl]phenol;hydrochloride
- Ractopamine hydrochloride (USP)
- Ractopamine hydrochloride [USAN:USP]
- BR162257
- Paylean 45, Paylean 9
- CAS-90274-24-1
- NSC 759638
- rac Ractopamine Hydrochloride (Mixture of Diastereomers)
-
- MDL： MFCD07781271
- Inchi： 1S/C18H23NO3.ClH/c1-13(2-3-14-4-8-16(20)9-5-14)19-12-18(22)15-6-10-17(21)11-7-15;/h4-11,13,18-22H,2-3,12H2,1H3;1H
- InChI Key： JHGSLSLUFMZUMK-UHFFFAOYSA-N
- SMILES： Cl.OC1C=CC(CCC(C)NCC(C2C=CC(O)=CC=2)O)=CC=1
Computed Properties
- Exact Mass: 337.14400
- Monoisotopic Mass: 301.167794
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 4
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 23
- Rotatable Bond Count: 7
- Complexity: 297
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 2
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 4
- XLogP3: nothing
- Topological Polar Surface Area: 72.7
Experimental Properties
- Color/Form: White to nearly white crystalline powder
- Melting Point: 165-167 oC
- Boiling Point: 542.3 °C at 760 mmHg
- Flash Point: 281.8 °C
- PSA: 72.72000
- LogP: 3.93500
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Security Information
- Signal Word：Warning
- Hazard Statement： H302+H332; H317
- Warning Statement： P261; P264; P270; P271; P272; P280; P301+P312; P302+P352; P304+P340; P312; P321; P330; P333+P313; P363; P501
- Hazard Category Code： R20/22;R43
- Safety Instruction： S24-S26-S37
-
Hazardous Material Identification：
- Risk Phrases：R20/22; R43
- Storage Condition：Store at room temperature
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Customs Data
- HS CODE：2922199090
- Customs Data：
China Customs Code:
2922111000Overview:
2922111000 Ractopamine and ractopamine hydrochloride.Regulatory conditions:89(Prohibited exports,Prohibited imports).VAT:17.0%.Tax refund rate:9.0%.Minimum tariff:6.5%.general tariff:30.0%
Summary:
2922111000 4-(1-hydroxy-2-((4-(4-hydroxyphenyl)butan-2-yl)amino)ethyl)phenol.supervision conditions:89(articles on the list of prohibited export goods,articles on the list of prohibited import goods).VAT:17.0%.tax rebate rate:9.0%.MFN tarrif:6.5%.general tariff:30.0%
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI YUAN YE Biotechnology Co., Ltd. | B25636-100mg |
Ractopamine Hydrochloride |
90274-24-1 | ,HPLC≥98% | 100mg |
￥2000.00 | 2021-09-02 | |
| TRC | R071400-50mg |
rac Ractopamine Hydrochloride (Mixture of Diastereomers) |
90274-24-1 | 50mg |
$ 91.00 | 2023-09-06 | ||
| TRC | R071400-100mg |
rac Ractopamine Hydrochloride (Mixture of Diastereomers) |
90274-24-1 | 100mg |
$ 108.00 | 2023-09-06 | ||
| TRC | R071400-200mg |
rac Ractopamine Hydrochloride (Mixture of Diastereomers) |
90274-24-1 | 200mg |
$181.00 | 2023-05-17 | ||
| TRC | R071400-500mg |
rac Ractopamine Hydrochloride (Mixture of Diastereomers) |
90274-24-1 | 500mg |
$249.00 | 2023-05-17 | ||
| TRC | R071400-1g |
rac Ractopamine Hydrochloride (Mixture of Diastereomers) |
90274-24-1 | 1g |
$374.00 | 2023-05-17 | ||
| TRC | R071400-5g |
rac Ractopamine Hydrochloride (Mixture of Diastereomers) |
90274-24-1 | 5g |
$ 541.00 | 2023-09-06 | ||
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | R96790-100mg |
Ractopamine Hydrochloride |
90274-24-1 | 100mg |
￥1998.0 | 2021-09-08 | ||
| A2B Chem LLC | AI60419-25mg |
Ractopamine HCl |
90274-24-1 | >98%(HPLC) | 25mg |
$32.00 | 2024-04-19 | |
| 1PlusChem | 1P00IGIR-25mg |
Ractopamine HCl |
90274-24-1 | >98%(HPLC) | 25mg |
$48.00 | 2024-04-20 |
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Production Method
Production Method 1
Reaction Conditions
1.1 Reagents: Hydrogen Catalysts: Palladium (with carbon) , Carbon (with palladium) Solvents: Ethanol
Reference
Production Method 2
Reaction Conditions
1.1 Reagents: Hydrogen Catalysts: Palladium
Reference
- Synthesis of ractopamine, China, , ,
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Raw materials
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Preparation Products
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Suppliers
Amadis Chemical Company Limited
Gold Member
Audited Supplier
(CAS:90274-24-1)rac Ractopamine Hydrochloride (Mixture of Diastereomers)
Order Number:A1191068
Stock Status:in Stock
Quantity:5g/1g
Purity:99%
Pricing Information Last Updated:Friday, 30 August 2024 02:14
Price ($):725.0/261.0
Email:[email protected]
Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier
(CAS:90274-24-1)Ractopamine hydrochloride
Order Number:LE12670
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:07
Price ($):discuss personally
Email:[email protected]
rac Ractopamine Hydrochloride (Mixture of Diastereomers) Related Literature
-
Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
-
Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
-
Wenjie Zhao,Hua Hou,Yuchun Jin,Zhixiang Zeng,Xuedong Wu,Qunji Xue RSC Adv., 2014,4, 60307-60315
-
Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
Additional information on rac Ractopamine Hydrochloride (Mixture of Diastereomers)
Professional Introduction to Rac Ractopamine Hydrochloride (Mixture of Diastereomers) and CAS No 90274-24-1
Rac Ractopamine Hydrochloride (Mixture of Diastereomers), identified by the chemical compound code CAS No 90274-24-1, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This mixture, comprising a racemic blend of diastereomers, has garnered considerable attention due to its unique pharmacological properties and potential applications in therapeutic interventions.
The compound belongs to the class of beta-adrenergic receptor agonists, which are widely utilized in the management of various medical conditions, particularly those related to cardiovascular and metabolic disorders. The racemic nature of Rac Ractopamine Hydrochloride implies that it contains equal proportions of both enantiomers, each with distinct but complementary biological activities. This characteristic makes it a subject of extensive research in understanding stereochemistry's role in drug efficacy and safety.
Recent advancements in the field have highlighted the importance of diastereomer mixtures in pharmaceutical development. Unlike enantiomers, which are mirror images of each other, diastereomers have different spatial arrangements that can lead to variations in pharmacokinetics and pharmacodynamics. The study of Rac Ractopamine Hydrochloride has provided valuable insights into how these differences can be leveraged to optimize therapeutic outcomes.
In clinical research, Rac Ractopamine Hydrochloride has been investigated for its potential benefits in managing conditions such as obesity and type 2 diabetes. The compound's ability to stimulate beta-adrenergic receptors leads to increased metabolic rate and improved insulin sensitivity, making it a promising candidate for weight management and glycemic control. However, the presence of diastereomers necessitates careful formulation and dosing strategies to ensure maximal efficacy while minimizing adverse effects.
One of the most intriguing aspects of Rac Ractopamine Hydrochloride is its mechanism of action. The diastereomer mixture exerts its effects through a complex interplay of receptor binding affinities and metabolic interactions. This complexity has prompted researchers to employ sophisticated computational models and experimental techniques to elucidate the structure-activity relationships within the mixture. Such studies are crucial for developing next-generation beta-adrenergic receptor agonists with enhanced selectivity and reduced side effects.
The pharmacological profile of Rac Ractopamine Hydrochloride has also been explored in preclinical models, where it has demonstrated potential in improving cardiovascular function and reducing fat accumulation. These findings have spurred interest in its use as an adjunct therapy for cardiovascular diseases, particularly those associated with metabolic syndrome. Additionally, the compound's anti-inflammatory properties have been noted, suggesting its possible role in modulating chronic inflammatory conditions.
From a regulatory perspective, the approval and commercialization of Rac Ractopamine Hydrochloride have been influenced by stringent guidelines aimed at ensuring drug safety and efficacy. Regulatory agencies require comprehensive data on the compound's pharmacokinetics, pharmacodynamics, and potential toxicities before granting market approval. The diastereomer mixture presents unique challenges in this regard, as it necessitates thorough characterization of each component's contribution to the overall therapeutic effect.
Future research directions for Rac Ractopamine Hydrochloride include exploring novel formulations that enhance its bioavailability and target specificity. Advances in nanotechnology and drug delivery systems have opened new avenues for optimizing the administration of this compound. Additionally, investigating its potential role in neurodegenerative diseases is an emerging area of interest, given its ability to modulate neural pathways associated with metabolism and cognition.
The industrial production of Rac Ractopamine Hydrochloride (Mixture of Diastereomers) requires precise synthetic methodologies to ensure high purity and consistency. Manufacturers must adhere to Good Manufacturing Practices (GMP) to guarantee that the final product meets regulatory standards. The synthesis process often involves multi-step reactions that require careful optimization to minimize impurities and byproducts.
Economic considerations also play a significant role in the development and distribution of Rac Ractopamine Hydrochloride. The cost-effectiveness of producing this compound compared to other available therapies is a critical factor for healthcare providers and patients alike. Furthermore, market dynamics such as patent expirations and generic competition can influence pricing strategies and market accessibility.
The environmental impact of manufacturing processes for Rac Ractopamine Hydrochloride is another important consideration. Sustainable practices are increasingly being adopted by pharmaceutical companies to reduce waste generation and energy consumption during production. These efforts align with broader industry initiatives aimed at promoting green chemistry principles.
In conclusion, Rac Ractopamine Hydrochloride (Mixture of Diastereomers) is a multifaceted compound with significant potential in pharmaceutical applications. Its unique stereochemical properties make it a subject of ongoing research, with implications for treating metabolic disorders, cardiovascular diseases, and possibly even neurodegenerative conditions. As scientific understanding advances, so too will our ability to harness its therapeutic benefits while ensuring safety and efficacy through innovative drug design and delivery systems.
90274-24-1 (rac Ractopamine Hydrochloride (Mixture of Diastereomers)) Related Products
- 26652-09-5(Ritodrine)
- 391234-95-0(1,3-Benzenediol,5-[(1S)-1-hydroxy-2-[[(1R)-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-)
- 97825-25-7(ractopamine)
- 13392-18-2(Fenoterol)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
Recommended suppliers
Amadis Chemical Company Limited
(CAS:90274-24-1)rac Ractopamine Hydrochloride (Mixture of Diastereomers)
Purity:99%/99%
Quantity:5g/1g
Price ($):725.0/261.0
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:90274-24-1)Ractopamine hydrochloride
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry